Compare Essex Property Trust, Inc. (ESS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Novo Nordisk A/S — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B), while Novo Nordisk A/S trades at $45.96 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 11.5× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ESS | NVO | |
|---|---|---|
Market Cap | $18.15B | $207.85B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $63.98 |
52-Week Low | $239.61 | $35.29 |
Enterprise Value | $24.75B | $222.55B |
Dividend Yield | 3.93% | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
